Association of lncRNA PVT1 Gene Polymorphisms with the Risk of Essential Hypertension in Chinese Population

Table 3

Association between lncRNA PVT1 polymorphisms and EH risk in the south of China.

Models	Genotypes	Control, (%)	EH, (%)	Unadjusted OR (95% CI)	value	Adjusted OR (95% CI)	Adjusted value
rs10956390
Additive	CC	75 (25.5)	92 (35.2)	1.00 (reference)		1.00 (reference)
	CT	149 (50.7)	120 (46.0)	0.657 (0.445-0.968)	0.034	0.610 (0.340-1.094)	0.097
	TT	70 (23.8)	49 (18.8)	0.571 (0.355-0.918)	0.021	0.657 (0.319-1.354)	0.254
Dominant	CC	75 (25.5)	92 (35.2)	1.00 (reference)		1.00 (reference)
	CT/TT	119 (74.5)	169 (64.8)	0.629 (0.437-0.906)	0.013	0.623 (0.357-1.085)	0.094
Recessive	CC/CT	224 (76.2)	212 (81.2)	1.00 (reference)		1.00 (reference)
	TT	70 (23.8)	49 (18.8)	0.740 (0.491-1.115)	0.150	0.911 (0.494-1.680)	0.766
rs80177647
Additive	TT	253 (86.1)	201 (77.0)	1.00 (reference)		1.00 (reference)
	TA	38 (12.9)	56 (21.5)	1.855 (1.181-2.914)	0.007	1.950 (1.023-3.718)	0.042
	AA	3 (1.0)	4 (1.5)	1.678 (0.371-7.585)	0.501	2.063 (0.183-23.305)	0.558
Dominant	TT	253 (86.1)	201 (77.0)	1.00 (reference)		1.00 (reference)
	TA/AA	41 (13.9)	60 (23.0)	1.842 (1.188-2.855)	0.006	1.956 (1.041-3.676)	0.037
Recessive	TT/TA	291 (99.0)	257 (98.5)	1.00 (reference)		1.00 (reference)
	AA	3 (1.0)	4 (1.5)	1.510 (0.335-6.809)	0.592	1.843 (0.163-20.785)	0.621

OR: odd ratio; CI: confidence interval; EH: essential hypertension. Adjusted for age, gender, BMI, smoking history, FBG, and dyslipidemia.